Fierce Biotech: Terremoto takes $108M series C to fuel clinical trials of AKT1 inhibitors
Terremoto Biosciences has spelt out how the California biotech will use a $108 million series C round to continue its efforts to broaden the covalent drug alphabet. | Terremoto Biosciences has spelt ...
Terremoto takes $108M series C to fuel clinical trials of AKT1 inhibitors
MarketWatch: Terremoto Biosciences Closes $108 Million Series C Financing to Advance Selective AKT1-Inhibitors in Oncology and Hereditary Hemorrhagic Telangiectasia
Terremoto Biosciences, a biotechnology company developing highly targeted, small molecule medicines, today announced the closing of a $108 million Series C financing round. The round includes new ...
Terremoto Biosciences Closes $108 Million Series C Financing to Advance Selective AKT1-Inhibitors in Oncology and Hereditary Hemorrhagic Telangiectasia